Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Cancer Prevention and the Hidden Risk of Obesity: VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA)

Obesity has become one of the most prevalent diseases in the United States. According to the Centers for Disease Control and Prevention, more than 35% of American adults are considered obese today, and rates of this disease among children are also increasing. VIVUS, Inc. (NASDAQ:VVUS)‘  Qsymia, an obesity drug that became available to physicians last September, and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)‘  Belviq, another FDA-approved drug for the treatment of obesity that should be launched in the coming weeks, are two new medications that can be prescribed in the fight against this disease. Both drugs are indicated for patients who are either obese, or overweight (i.e., BMI more than 27) and also suffer from hypertension, diabetes, or high levels of cholesterol in their bloodstream.

Arena Pharmaceuticals, Inc.This may not be a surprise, since obesity is commonly associated with heart problems and cholesterol, but did you know that obesity can also lead to specific types of cancer? The World Cancer Research Fund states that overweight or obese patients can be at increased risk of developing colorectal, pancreatic, kidney, and breast cancers. Whether obesity-fighting drugs will be able to play a direct role in mitigating this risk going forward is debatable, but preventing and treating this disease in the future is one component in the fight against cancer.

Dr. Margaret I. Cuomo, author of the book A World Without Cancer, discusses this topic with Motley Fool analyst Max Macaluso in the following video. A transcript is provided below the video.

Opportunities and risks in the obesity drug market
Biotech companies focusing on treatments for obesity may have massive opportunities, but they also face a number of risks. Can VIVUS, Inc. (NASDAQ:VVUS) pick up its lagging sales and fend off the competition, or will Arena Pharmaceuticals (NASDAQ:ARNA) reign supreme in this space? If you’re in the dark, grab copies of The Motley Fool’s premium research reports on VIVUS and Arena Pharmaceuticals to stay up to date. Senior biotech analyst Brian Orelli gives investors the must-know information, including an in-depth look at the obesity market and reasons to buy and sell both stocks. Click now for an exclusive look at Arena and VIVUS — complete with a full year of free updates — today.

Max Macaluso: Let’s talk a little bit about obesity. I think a lot of people might not realize that obesity is linked to certain types of cancers.

Dr. Margaret I. Cuomo: Yes. Obesity is linked to quite a few cancers. Scientists have pointed to the fact that breast cancer and colon cancer are definitely linked to obesity, but there are many other cancers that are as well.

What do we want to do? How do we avoid this epidemic? Do you realize, in the past 30 years the rate of obesity among children has tripled, and it has doubled for adults? Everyone agrees we have an epidemic. What do we do about it?

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.